R-CODOX-M/R-IVAC对比DA-EPOCH-R治疗新诊断伯基特淋巴瘤(HOVON/SAKK):多中心3期开放标签随机试验最终结果
这项多中心3期开放标签随机试验在荷兰、比利时和瑞士26个中心比较R-CODOX-M/R-IVAC与DA-EPOCH-R治疗18-75岁新诊断高危伯基特淋巴瘤无中枢神经系统受累患者,因入组缓慢于2021年11月15日提前终止,84例纳入改良意向治疗分析。中位随访28.5个月,2年无进展生存率R-CODOX-M/R-IVAC组76%(95%CI 60-86%)vs DA-EPOCH-R组70%(54-82%)(HR 1.42,95%CI 0.63-3.18;p=0.40)。DA-EPOCH-R未显示优效,但毒性反应和支持治疗需求更少。
要点
- 2年无进展生存率R-CODOX-M/R-IVAC组76% vs DA-EPOCH-R组70%(HR 1.42,95%CI 0.63-3.18;p=0.40)。
- R-CODOX-M/R-IVAC组43例中24例(56%)发生至少一次3-5级感染,DA-EPOCH-R组41例中14例(34%)。
- R-CODOX-M/R-IVAC组4例因毒性退出方案,DA-EPOCH-R组无因毒性退出。
核心结论
- 试验提前终止,但现有数据提示DA-EPOCH-R相比R-CODOX-M/R-IVAC未获得更优的无进展生存,且毒性反应和支持治疗需求更少。
- DA-EPOCH-R似乎是无中枢神经系统受累的高危伯基特淋巴瘤患者的另一种有效治疗选择。
研究设计与样本
- 多中心、3期、开放标签、随机试验,在荷兰、比利时和瑞士26个临床中心进行。
- 纳入18-75岁新诊断高危伯基特淋巴瘤无中枢神经系统受累患者,随机分配至两周期R-CODOX-M/R-IVAC(n=46)或六周期DA-EPOCH-R(n=43)。
- 因入组缓慢于2021年11月15日提前终止;2014年8月4日至2021年9月17日入组89例,随机后排除5例,84例纳入改良意向治疗分析。
- 主要终点为无进展生存;按中心、白血病性疾病和HIV阳性分层。
主要发现
- 84例中73例(87%)为男性,76例(90%)为III或IV期疾病,9例(11%)为HIV阳性伯基特淋巴瘤;中位年龄52岁(IQR 37-64)。
- 中位随访28.5个月(IQR 13.2-43.7),2年无进展生存率R-CODOX-M/R-IVAC组76%(95%CI 60-86%)vs DA-EPOCH-R组70%(54-82%)(HR 1.42,95%CI 0.63-3.18;p=0.40)。
- R-CODOX-M/R-IVAC组2例死亡(1例感染[治疗相关],1例疾病进展[非治疗相关]),DA-EPOCH-R组1例死亡(COVID-19感染[治疗相关])。
- R-CODOX-M/R-IVAC组43例中24例(56%)发生至少一次3-5级感染,DA-EPOCH-R组41例中14例(34%)。
- R-CODOX-M/R-IVAC组4例因毒性退出方案,DA-EPOCH-R组无因毒性退出。
临床怎么用
- 作者认为,DA-EPOCH-R似乎是无中枢神经系统受累的高危伯基特淋巴瘤患者的另一种有效治疗选择。
局限性
- 因入组缓慢,研究于2021年11月15日提前终止。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Patients with newly diagnosed high-risk Burkitt lymphoma are treated with high-intensity immune-chemotherapy regimens such as R-CODOX-M/R-IVAC or with lower-intensity regimens such as DA-EPOCH-R. The aim of this study was to make a formal comparison between these regimens. METHODS: This multicentre, phase 3, open-label, randomised study was done in 26 clinical centres in the Netherlands, Belgium, and Switzerland. Eligible patients were aged 18-75 years with newly diagnosed high-risk Burkitt lymphoma without CNS involvement. Patients were randomly assigned to two cycles of R-CODOX-M/R-IVAC (R-CODOX-M: rituximab 375 mg/m2 on day 1 and 9, cyclophosphamide 800 mg/m2 on day 1, cyclophosphamide 200 mg/m2 on days 2-5, vincristine 1·5 mg/m2 on days 1 and 8, doxorubicin 40 mg/m2 on day 1, and methotrexate 3000 mg/m2 on day 10; R-IVAC: rituximab 375 mg/m2 on days 3 and 7, iphosphamide 1500 mg/m2 on days 1-5, etoposide 60 mg/m2 on days 1-5, and cytarabin 2000 mg/m2 on day 1 and 2) or six cycles of DA-EPOCH-R (dose-adjusted etoposide 50-124 mg/m2 on days 1-4, prednisolone 120 mg/m2 on days 1-5, vincristine 0·4 mg/m2 on days 1-4, dose-adjusted cyclophosphamide 480-1866 mg/m2 on day 5, dose-adjusted doxorubicin 10-24·8 mg/m2 on days 1-4, rituximab 375 mg/m2 on days 1 and 5). Patients older than 65 years received a dose modified R-CODOX-M/R-IVAC. All drugs were intravenous except for prednisolone, which was oral. Patients also received four intrathecal CNS administrations with cytarabin (70 mg) and four with methotrexate (15 mg). Patients were stratified by centre, leukemic disease, and HIV-positivity. The primary endpoint was progression-fee survival. All analyses were done by modified intention-to-treat, excluding randomly assigned patients who were subsequently found to have CNS involvement or diagnosis other than Burkitt lymphoma at study entry. This study is registered with the European Clinical Trial Register, EudraCT2013-004394-27. FINDINGS: Due to a slow accrual, the study was closed prematurely on Nov 15, 2021. Between Aug 4, 2014, and Sept 17, 2021, 89 patients were enrolled and randomly assigned to receive R-CODOX-M/R-IVAC (n=46) or DA-EPOCH-R (n=43). Five patients were excluded after random assignment (three in the R-CODOX-M/R-IVAC group [one diagnosis other than Burkitt lymphoma at study entry according to local pathology and two CNS involvement] and two in the DA-EPOCH-R group [one diagnosis other than Burkitt lymphoma at study entry according to local pathology and one CNS involvement]. 84 remaining patients were included in the modified intention-to-treat analysis. 73 (87%) of 84 patients were male, 76 (90%) presented with stage III or IV disease, and nine (11%) had HIV-positive Burkitt lymphoma. Median patient age was 52 years (IQR 37-64). With a median follow-up of 28·5 months (IQR 13·2-43·7), 2-year progression-free survival was 76% (95% CI 60-86%) in the R-CODOX-M/R-IVAC group and 70% (54-82%) in the DA-EPOCH-R group (hazard ratio 1·42, 95% CI 0·63-3·18; p=0·40). There were two deaths in the R-CODOX-M/R-IVAC group (one infection [treatment related] and one due to disease progression [not treatment related]) and one death in the DA-EPOCH-R group (COVID-19 infection [treatment related]). In the R-CODOX-M/R-IVAC group, four patients went off-protocol because of toxic effects, versus none in the DA-EPOCH-R group. Patients treated with R-CODOX-M/R-IVAC had more infectious adverse events (24 [56%] of 43 patients had at least one grade 3-5 infection vs 14 [34%] of 41 patients in the DA-EPOCH-R group). INTERPRETATION: The trial stopped early, but the available data suggest that while DA-EPOCH-R did not result in superior progression-free survival compared with R-CODOX-M/R-IVAC, it was associated with fewer toxic effects and need for supportive care. DA-EPOCH-R appears to be an additional valid therapeutic option for patients with high-risk Burkitt lymphoma without CNS involvement. FUNDING: The Dutch Cancer Society and the Schumacher-Kramer Foundation.
引用
- Chamuleau MED, Stenner F, Chitu DA, et al. R-CODOX-M/R-IVAC versus DA-EPOCH-R in patients with newly diagnosed Burkitt lymphoma (HOVON/SAKK): final results of a multicentre, phase 3, open-label, randomised trial. Lancet Haematol. 2023. PMID: 37922925. doi:10.1016/S2352-3026(23)00279-X
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。